Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Doramapimod (BIRB796)

Catalog No: tcsc0219

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Specifications

CAS No:
285983-48-4

Formula:
$C_{31}H_{37}N_5O_3$

Pathway:
MAPK/ERK Pathway;MAPK/ERK Pathway

Target:
p38 MAPK;Raf

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 100 mg/mL (189.52 mM); H2O :

Alternative Names:
BIRB 796

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
527.66

Product Description

Doramapimod is a highly potent **p38α** inhibitor with an **IC_{50}** of 4 nM, also inhibits **B-Raf** with an **IC_{50}** of 83 nM and Abl with an IC_{50} of 14.6 μM.

IC50 & Target: IC50: 4 nM (p38α), 83 nM (B-Raf)[1]

In Vitro: Doramapimod (BIRB 796) is a highly potent inhibitor of p38α, a serine/threonine mitogen activated protein kinase (MAPK) that is usually associated with inflammation because of its role in T-cell proliferation and cytokine production[1]. Doramapimod (BIRB 796) is a picomolar inhibitor of human p38 MAP kinase[2]. HEK293 cells are incubated with different concentrations of Doramapimod (BIRB 796) for 30 min or 2 h prior to stimulation with sorbitol (an osmotic shock) and examined the activation of MAPKAP-K2 by measuring its activity. MAPKAP-K2 activation is inhibited in these cells in a time-dependent manner with an apparent IC_{50} of 30 nM after 30 min or 8 nM after 2 h of preincubation with Doramapimod[3].

In Vivo: The mean xenograft weigh of Doramapimod (BIRB 796) plus Paclitaxel group (1.14±0.48 g) is lighter than control, Doramapimod or Paclitaxel group (1.84±0.61, 1.80±0.62 and 1.65±0.29 g) (P[4]. The Doramapimod (BIRB 796) treatment slightly reduces blood pressure (166±7 mm Hg at week 7; P[5].